AstraZeneca (AZN) closed at $165.40 on Oct 16, 2026, down 0.8% on the day. The stock is down 0.4% over the past month, up 0.5% over three months, down 9.1% year to date and down 1.5% over the past year. It trades 21.4% below its 52-week high of $210.52 and 7.8% above its 52-week low of $153.41. The close sits above its 50-day moving average ($162.13) and below its 200-day moving average ($180.63).
NextPick tracks AZN in its Pharma basket alongside JNJ, ABBV, MRK, RHHBY and NVS. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month AZN ranks 7th of 12 basket members by price change.
AZN is scheduled to report earnings on Oct 30, 2026. Over its last 8 reports the stock moved an average of 1.9% on the first trading day after earnings, beating the options-implied move in 0 of 8.
AstraZeneca is scheduled to report on Oct 30, 2026.
Over the last 8 reports, AZN moved an average of 1.9% on the first trading day after earnings. The move beat the options-implied move in 0 of 8 reports.
No — the Oct 16, 2026 close of $165.40 is 8.4% below the 200-day average of $180.63.
AZN closed 21.4% below its 52-week high of $210.52.
NextPick groups AZN with JNJ, ABBV, MRK, RHHBY and NVS in its Pharma basket.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
